A 48-year-old man with chronic hepatitis C virus (HCV) genotype 1 infection seeks therapy. Recent labs show persistently elevated ALT and HCV RNA >800,000 IU/mL. Liver biopsy demonstrates moderate fibrosis (stage F2). He has no contraindications to antiviral therapy. He is to receive a regimen of direct-acting antivirals that specifically target the HCV NS3/4A protease and the NS5B RNA-dependent RNA polymerase. Which combination of drugs best fits this regimen?